Head and Neck TumorsHead and Neck TumorsОпухоли головы и шеи2222-14682411-4634Publishing House ABV Press7210.17650/2222-1468-2012-0-2-88-91ORIGINAL REPORTSОРИГИНАЛЬНЫЕ ИССЛЕДОВАНИЯTHERAPEUTIC EFFECT OF SOLASODINE RHAMNOSYL GLYCOSIDES FOR LARGE SKIN CANCERS: TWO CLINICAL CASESЛЕЧЕБНЫЙ ЭФФЕКТ СОЛАСОДИН-РАМНОЗИЛОВЫХ ГЛИКОЗИДОВ ПРИ КРУПНЫХ ЗЛОКАЧЕСТВЕННЫХ ОПУХОЛЯХ КОЖИ (ДВА КЛИНИЧЕСКИХ СЛУЧАЯ)E. ChamBillЧамБилл
Vanuatu
abada82@mail.ruAustralasian Medical Research, Devil’s Point Road, Port VilaАвстралазийские медицинские исследования, Порт-Вила150420122288911804201518042015Copyright ©; 2012, E. Cham B.Copyright ©; 2012, Чам Б.2012E. Cham B.Чам Б.https://creativecommons.org/licenses/by/4.0https://ogsh.abvpress.ru/jour/article/view/72

Solasodine rhamnosyl glycosides (BEC) are a new class of antineoplastics, the efficiency of which administered via intravenous, intraperitoneal, and intratumoral routes is higher than that of many other antitumor agents. Early investigations have established the efficiency of topical BEC applications as a treatment option for non-melanoma skin cancers. There have recently been two clinical cases that count in favor of the fact that the cream formulation Curaderm containing BEC has a very high efficacy in the treatment of large non-melanoma skin cancers that are incurable by other existing methods. Also, Curaderm treatment shows a splendid cosmetic effect. 

Соласодин-рамнозиловые гликозиды (СРГ) являются новым классом противоопухолевых препаратов, эффективность которых при внутривенном, интраперитонеальном и внутриопухолевом введении оказалась выше, чем у многих других противоопухолевых веществ. Эффективность местных аппликаций СРГ как метода лечения немеланоцитарных злокачественных опухолей (ЗО) кожи была установлена в ранее проведенных исследованиях. Недавно было представлено 2 клинических случая, которые свидетельствуют в пользу того, что крем курадерм, содержащий СРГ, обладает очень высокой эффективностью при лечении крупных немеланоцитарных ЗО кожи, которые трудно поддаются лечению с помощью других существующих методов. Кроме того, лечение с помощью курадерма характеризуется великолепным косметическим эффектом. 

non-melanoma skin cancerssolasodine rhamnosyl glycosidescuradermsolamarginesolasonineнемеланоцитарные злокачественные опухоли кожисоласодин-рамнозиловые гликозидыкурадермсоламаргинсоласонин1. Rogers H.W., Weinstock N.A., Harris A.R. et al. Incidence estimate of nonmelanoma skin cancer in the United States. Arch Dermatol 2010;146(3):283−7.Rogers H.W., Weinstock N.A., Harris A.R. et al. Incidence estimate of nonmelanoma skin cancer in the United States. Arch Dermatol 2010;146(3):283−7.2. Sussman L.A. and Liggins D.F. Incompletely excised basal cell carcinoma a management dilemma? Aust N Z J Surg 1996;66:276−8.Sussman L.A. and Liggins D.F. Incompletely excised basal cell carcinoma a management dilemma? Aust N Z J Surg 1996;66:276−8.3. Kuo K.W., Hsu S.H., Li Y.P. et al. Anticancer activity evaluation of the solanum glycoalkaloid solamargine. Triggering apoptosis in human hepatoma cells. Biochem Pharmacol 2000;60:1865−73.Kuo K.W., Hsu S.H., Li Y.P. et al. Anticancer activity evaluation of the solanum glycoalkaloid solamargine. Triggering apoptosis in human hepatoma cells. Biochem Pharmacol 2000;60:1865−73.4. Liang C.H., Liu L.F., Shiu L.Y. et al. Action of solamargine on TNFs and cisplatin-resistant human lung cancer cells. Biochem Biophys Res Commun 2004;322(3):751−8.Liang C.H., Liu L.F., Shiu L.Y. et al. Action of solamargine on TNFs and cisplatin-resistant human lung cancer cells. Biochem Biophys Res Commun 2004;322(3):751−8.5. Shiu L.Y., Chang L.C., Liang C.H. et al. Solamargine induces apoptosis and sensitizes breast cancer cells to cisplatin. Food Chem Toxicol 2007;45(11):2155−64.Shiu L.Y., Chang L.C., Liang C.H. et al. Solamargine induces apoptosis and sensitizes breast cancer cells to cisplatin. Food Chem Toxicol 2007;45(11):2155−64.6. Shiu L.Y., Liang C.H., Huang Y.S. et al. Downregulation of HER2/neu receptor by solamargine enhances anticancer drugmediated cytotoxicity in breast cancer cells with high-expressing HER2/neu. Cell Biol Tox 2008;24(1):1−10.Shiu L.Y., Liang C.H., Huang Y.S. et al. Downregulation of HER2/neu receptor by solamargine enhances anticancer drugmediated cytotoxicity in breast cancer cells with high-expressing HER2/neu. Cell Biol Tox 2008;24(1):1−10.7. Sun L., Zhao Y., Yuan H. et al. Solamargine, a steroidal alkaloid glycoside, induces oncosis in human K562 leukemia and squamous cell carcinoma KB cells. Cancer Chemother Pharmacol 2010; 65:1125−30.Sun L., Zhao Y., Yuan H. et al. Solamargine, a steroidal alkaloid glycoside, induces oncosis in human K562 leukemia and squamous cell carcinoma KB cells. Cancer Chemother Pharmacol 2010; 65:1125−30.8. Cham B.E., Daunter B. Solasodine glycosides. Selective cytotoxicity for cancer cells and inhibition of cytotoxicity by rhamnose in mice with sarcoma 180. Cancer Letters 1990;55:221−5.Cham B.E., Daunter B. Solasodine glycosides. Selective cytotoxicity for cancer cells and inhibition of cytotoxicity by rhamnose in mice with sarcoma 180. Cancer Letters 1990;55:221−5.9. Daunter B., Cham B.E. Solasodine glycosides. In vitro preferential cytotoxicity for human cancer cells. Cancer Letters 1990;55:209−20.Daunter B., Cham B.E. Solasodine glycosides. In vitro preferential cytotoxicity for human cancer cells. Cancer Letters 1990;55:209−20.10. Millward M., Powell A., Daly P. et al. Results of phase I clinical trials of Coramsine in patients with advanced solid tumours. J Clin Oncol 2006;24:2070.Millward M., Powell A., Daly P. et al. Results of phase I clinical trials of Coramsine in patients with advanced solid tumours. J Clin Oncol 2006;24:2070.11. Cham B.E., Gilliver M., Wilson L. Antitumour effects of glycoalkaloids isolated from Solanum sodomaeum. Planta Med 1987;53:34−6.Cham B.E., Gilliver M., Wilson L. Antitumour effects of glycoalkaloids isolated from Solanum sodomaeum. Planta Med 1987;53:34−6.12. Cham B.E. Cancer intralesion chemotherapy with solasodine rhamnosyl glycosides. Res J Biol Sci 2008;3(9):1008−17.Cham B.E. Cancer intralesion chemotherapy with solasodine rhamnosyl glycosides. Res J Biol Sci 2008;3(9):1008−17.13. Cham B.E. Solasodine rhamnosyl glycosides specifically bind cancer cell receptors and induce apoptosis and necrosis. Treatment for skin cancer and hope for internal cancers. Res J Biol Sci 2007; 2(4):503−14.Cham B.E. Solasodine rhamnosyl glycosides specifically bind cancer cell receptors and induce apoptosis and necrosis. Treatment for skin cancer and hope for internal cancers. Res J Biol Sci 2007; 2(4):503−14.14. Cham B.E., Daunter B., Evans R. Topical treatment of malignant and premalignant skin cancers by very low concentrations of a standard mixture of solasodine glycosides. Cancer Letters 1991;59:183−92.Cham B.E., Daunter B., Evans R. Topical treatment of malignant and premalignant skin cancers by very low concentrations of a standard mixture of solasodine glycosides. Cancer Letters 1991;59:183−92.15. Cham B.E. Solasodine rhamnosyl glycosides in a cream formulation is effective for treating large and troublesome skin cancers. Res J Biol Sci 2007;2(7):749−61.Cham B.E. Solasodine rhamnosyl glycosides in a cream formulation is effective for treating large and troublesome skin cancers. Res J Biol Sci 2007;2(7):749−61.16. Cham B.E., Meares M.M. Glycoalkaloids from Solanum sodomaeum are effective in the treatment of skin cancers in man. Cancer Letters 1987;36:111−8.Cham B.E., Meares M.M. Glycoalkaloids from Solanum sodomaeum are effective in the treatment of skin cancers in man. Cancer Letters 1987;36:111−8.17. Punjabi S., Cook L.J., Kersey P. et al. Solasodine glycoalkaloids: a novel topical therapy for basal cell carcinoma. A doubleblind, randomized, placebo-controlled, parallel group, multicentre study. Internat J Dermatol 2008;47:78−82.Punjabi S., Cook L.J., Kersey P. et al. Solasodine glycoalkaloids: a novel topical therapy for basal cell carcinoma. A doubleblind, randomized, placebo-controlled, parallel group, multicentre study. Internat J Dermatol 2008;47:78−82.18. Kuo K.W., Lin C.N. Pharmacological composition for treating cancer cells. United States Patent 6, 1999. Pp. 214−803.Kuo K.W., Lin C.N. Pharmacological composition for treating cancer cells. United States Patent 6, 1999. Pp. 214−803.19. Shiu L.Y., Chang L.C., Liang C.H. et al. Solamargine induces apoptosis and sensitizes breast cancer cells to cisplatin. Food Chem Toxicol 2007;45(11):2155−64.Shiu L.Y., Chang L.C., Liang C.H. et al. Solamargine induces apoptosis and sensitizes breast cancer cells to cisplatin. Food Chem Toxicol 2007;45(11):2155−64.